Yinhua CSI Innovative Drugs Industry ETF (159992) Rises 2.04%, Aiming for Third Consecutive Gain

NewTimeSpace News, as of 13:21 on May 21, 2026, Yinhua Innovative Drug ETF (159992) rose 2.04%, aiming for a third consecutive gain. The latest quoted price is 0.8 yuan. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Yinhua Innovative Drug ETF recorded an intraday turnover rate of 3.83%, with a trading volume of 577 million yuan. Over a longer horizon, as of May 20, the ETF's average daily turnover over the past week stood at 667 million yuan, ranking first among comparable funds.

Regarding scale, Yinhua Innovative Drug ETF's AUM increased by 1.656 billion yuan over the past six months, achieving significant growth, with the new scale increment ranking 2/7 among comparable funds. (Data source: Wind)

In terms of share size, Yinhua Innovative Drug ETF's share count increased by 497 million units over the past two weeks, achieving significant growth, with the new share increment ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital inflows, the latest net outflow for Yinhua Innovative Drug ETF was 14.5778 million yuan. Looking at a longer timeframe, over the past ten trading days, the total net inflow amounted to 406 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The net margin purchase amount for Yinhua Innovative Drug ETF month-to-date reached 4.5478 million yuan, and the latest margin balance stood at 637 million yuan. (Data source: Wind)

As of May 20, Yinhua Innovative Drug ETF's net value increased by 12.36% over the past two years. In terms of return capability, as of May 20, 2026, since its inception, the ETF achieved a highest single-month return of 22.79%, a longest consecutive gaining streak of four months with a cumulative gain of 53.27%, and an average return of 6.47% during up months. As of May 20, 2026, the ETF's annualized excess return over its benchmark over the past two years was 0.64%.

In terms of drawdown, as of May 20, 2026, Yinhua Innovative Drug ETF's relative drawdown versus its benchmark since the beginning of the year was 0.18%.

In terms of fees, Yinhua Innovative Drug ETF has a management fee rate of 0.50% and a custody fee rate of 0.05%.

In terms of tracking accuracy, as of May 20, 2026, Yinhua Innovative Drug ETF's one-month tracking error was 0.011%, the highest tracking precision among comparable funds.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Innovative Drug Industry Index, which Yinhua Innovative Drug ETF tracks, is only 45.43 times, placing it at the 11.83rd percentile over the past year—meaning the valuation is lower than that of over 88.17% of the time in the past year, indicating a historically low level.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main business involves innovative drug research and development as index constituents, in order to reflect the overall performance of listed company securities in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.